Asabys Partners Expands, Merges with AltamarCAM to Dominate European Life Sciences
Asabys Partners, a prominent European life science investor, has revealed a substantial expansion. The firm, founded in 2018, has backed 18 companies and witnessed two successful exits. Now, it's merging with AltamarCAM Partners, creating a robust investment platform in Europe's competitive life science sector.
The unification will see Asabys' assets under management (AUM) grow from €300m to over €400m. Long-term plans aim to surpass €1bn by 2030. The combined team will fortify and consolidate the Spanish GP landscape, enabling Asabys to expand its assets and grow its team.
The integration includes the co-management of the Alta Life Sciences Spain I FCR fund by Asabys and AltamarCAM. Asabys' founding partners will join the fund's investment committee. Two new partners, Álvaro Fernández and Pablo Bellón, will take over Asabys' partners in the fund's co-management. Montserrat Vendrell and José María Fernández from Aliath Bioventures will also become partners at Asabys.
The investment teams from both firms have collaborated and co-invested in several companies, including Deepull, Ona Therapeutics, and Inbrain Neuroelectronics. Asabys plans to launch two new funds between 2026 and 2027, focusing on European investments, particularly within Spain.
With this integration, Asabys strengthens its position in Europe's life science sector. The expanded team and increased AUM will enable the firm to invest in more innovative companies, driving growth and success in the industry.
